Viking Therapeutics reports Q3 EPS (81c), consensus (67c)

At September 30, Viking held cash, cash equivalents and short-term investments of $715M vs. $903M as of December 31, 2024. “During the first three quarters of 2025, Viking made strong and steady progress with each of our active programs, with new data reported in the third quarter that further positions our lead obesity program as potentially best-in-class,” stated CEO Brian Lian. “In Q3, we announced positive top-line results from the Phase 2 VENTURE-Oral Dosing study of VK2735, which successfully achieved its primary and secondary endpoints, with patients receiving VK2735 demonstrating statistically significant reductions in body weight of up to 12.2% from baseline…The impressive oral efficacy and low-dose maintenance data highlight VK2735’s differentiated profile, offering additional dosing options to complement weekly subcutaneous dosing. In Q2, Viking initiated the Phase 3 VANQUISH registration program, including trials in patients with obesity and obesity with type 2 diabetes. Enrollment in these trials is proceeding well. We expect to complete enrollment in the VANQUISH-1 study later this quarter, with VANQUISH-2 to follow in Q1 of 2026…Finally, we made good progress in Q3 with our amylin agonist program and plan to file an IND in Q1 of 2026. Importantly, our balance sheet remains strong, providing sufficient resources to enable the development of VK2735 through the VANQUISH Phase 3 clinical trials, and to continue development of additional clinical programs in our pipeline.”